Company news
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news
Every Sarepta Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 5
Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
July 24, 2020
Sarepta Therapeutics Launches “Rare Lessons” Program to Promote Greater Diversity and Inclusion in the Classroom and Support Awareness of Rare Diseases
July 15, 2020
Sarepta Therapeutics Signs Agreement with Hansa Biopharma for Imlifidase
July 2, 2020
Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer
June 30, 2020
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45
June 26, 2020
Sarepta Therapeutics and Codiak BioSciences Collaborate to Research and Develop Exosome-Based Therapeutics for Rare Diseases
June 22, 2020
Sarepta Therapeutics Announces Positive Safety and Efficacy Data from the SRP-9001 Micro-Dystrophin Gene Therapy Trial Published in JAMA Neurology
June 15, 2020
Sarepta Therapeutics Announces Positive Expression and Functional Data From the SRP-9003 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E
June 8, 2020
Sarepta Therapeutics to Share Clinical Update from SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
June 5, 2020
Sarepta Therapeutics to Present at the 2020 RBC Capital Markets Virtual Global Healthcare Conference
May 12, 2020
Sarepta Therapeutics and Dyno Therapeutics Announce Agreement to Develop Next-Generation Gene Therapy Vectors for Muscle Diseases
May 11, 2020
Sarepta Therapeutics Announces First Quarter 2020 Financial Results and Recent Corporate Developments
May 6, 2020
Sarepta Therapeutics to Announce First Quarter 2020 Financial Results and Recent Corporate Developments on May 6, 2020
April 29, 2020
Sarepta Therapeutics Announces Research Agreement with U.S. Department of Defense to Evaluate Multiple Constructs From its Proprietary RNA Platform as Treatments for COVID-19
April 28, 2020
Sarepta Therapeutics Announces Third Year of Route 79, The Duchenne Scholarship Program
February 27, 2020
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments
February 26, 2020
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments on February 26, 2020
February 19, 2020
Sarepta Therapeutics Appoints Renowned Biotech Executive John C. Martin to its Board of Directors
January 13, 2020
Sarepta Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 6, 2020
Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001
December 23, 2019
Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan Financing
December 13, 2019
Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53
December 12, 2019
Sarepta and StrideBio Announce Multi-target Strategic Collaboration to Advance Novel Gene Therapies
November 14, 2019
Sarepta Therapeutics Announces Third Quarter 2019 Financial Results and Recent Corporate Developments
November 7, 2019
Sarepta Therapeutics to Present at the Credit Suisse 28th Annual Healthcare Conference
November 5, 2019
Sarepta Therapeutics to Announce Third Quarter 2019 Financial Results and Recent Corporate Developments on November 7, 2019
October 24, 2019
Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
October 4, 2019
Sarepta Therapeutics to Announce 9-Month Functional Results from the SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
September 25, 2019